New lab research suggests Lapatinib will be effective after resistance to Herceptin
The authors attach importance to their finding that Lapatinib inhibits insulin-like growth factor I (IGF-I): if this is true for humans it may mean that Lapatinib can prevent or delay one of the ways cancer cells become resistant to Herceptin.
This might also mean that concurrent administration of the two drugs may be better than sequential administration although this is not said in the abstract & may need to be demonstrated in trials. http://mct.aacrjournals.org/cgi/cont...stract/6/2/667 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling |
EGCG green tea extract as a possible inhibitor of IGF-IR activity
In this mice study , EGCG prevents the receptor for IGF-I from being activated,
a function regarded as important in the previous post on Tykerb. http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation |
All times are GMT -7. The time now is 05:41 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021